Antag Therapeutics
@antagtherapeutics.com
Antag Therapeutics is a biotechnology company pioneering personal and flexible obesity treatment through GIP receptor antagonism. Antag’s lead molecule AT-7687 is specifically designed to target and deactivate the GIP receptor, a genetically-validated pathway that contributes to fat storage, insulin resistance, and metabolic dysfunction – and is mechanistically distinct from GLP-1 therapies. Antag’s GIPR antagonist approach stems from the work of the esteemed research teams of Professors Jens Juul Holst and Mette Rosenkilde, two co-founders of the business. Antag’s vision is that all people living with obesity, diabetes and overweight have a personal treatment option that goes beyond weight loss to improve long-term health, without having to compromise on tolerability.
Antag Therapeutics's Company Logos
Antag Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#8B8B8B
Gray
139, 139, 139
0, 0, 55
0, 0, 0, 45
#C49FE5
Biloba Flower
196, 159, 229
272, 57, 76
14, 31, 0, 10
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#B7305E
Hibiscus
183, 48, 94
340, 58, 45
0, 74, 49, 28
About Antag Therapeutics
Antag Therapeutics is a preclinical stage biotechnology company dedicated to developing innovative therapeutic peptides for metabolic and cardiovascular autonomic diseases. With a focus on understanding and targeting incretin physiology, our research teams, led by Professors Jens Juul Holst and Mette Rosenkilde from the University of Copenhagen, have discovered a novel endogenous peptide antagonist. Our therapeutic peptides, optimized analogues of the GIP receptor inhibitor found in the human body, offer a promising solution for conditions such as postural orthostatic tachycardia syndrome (POTS) and obesity.
POTS affects millions of people in the US, leading to reduced quality of life and a lack of approved treatments. Similarly, obesity has become a global health crisis, often resulting in comorbidities like type 2 diabetes and fatty liver disease. At Antag Therapeutics, we aim to provide once-weekly self-administrable subcutaneous injections that surpass current interventions in terms of effectiveness.
Our dedicated team, including industry leaders like CEO Philip Just Larsen and Chief Scientific Officer Mads T. Christensen, brings decades of experience in research, development, and strategic leadership. Stay updated with our latest advancements in the field of therapeutic peptides by following Antag Therapeutics on our website and social media platforms
Company type
Privately Held
Year founded
2017
Company size
2-10 employees
